Cargando…

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirze...

Descripción completa

Detalles Bibliográficos
Autores principales: MacIsaac, Richard J., Deed, Gary, D’Emden, Michael, Ekinci, Elif I., Hocking, Samantha, Sumithran, Priya, Rasalam, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597955/
https://www.ncbi.nlm.nih.gov/pubmed/37824027
http://dx.doi.org/10.1007/s13300-023-01475-5
_version_ 1785125450885890048
author MacIsaac, Richard J.
Deed, Gary
D’Emden, Michael
Ekinci, Elif I.
Hocking, Samantha
Sumithran, Priya
Rasalam, Roy
author_facet MacIsaac, Richard J.
Deed, Gary
D’Emden, Michael
Ekinci, Elif I.
Hocking, Samantha
Sumithran, Priya
Rasalam, Roy
author_sort MacIsaac, Richard J.
collection PubMed
description Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits, combined with low rates of hypoglycaemia across a wide range of patient characteristics. The safety and adverse event rate for tirzepatide appears comparable to that of GLP-1 receptor agonists. Although results from dedicated cardiovascular (CV) and kidney trials are currently not available, information to date suggests that tirzepatide may have CV and kidney benefits in people with T2D. Tirzepatide has been approved for the treatment of T2D in the USA, United Arab Emirates, European Union, Japan and Australia. Here, we review how tirzepatide will fit into the T2D treatment continuum. We also consider future directions with tirzepatide in T2D, including its potential for targeting cardio-renal-metabolic disease in T2D, and discuss how tirzepatide—and other co-agonists in development—may challenge current approaches for management of T2D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01475-5.
format Online
Article
Text
id pubmed-10597955
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-105979552023-10-26 Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin MacIsaac, Richard J. Deed, Gary D’Emden, Michael Ekinci, Elif I. Hocking, Samantha Sumithran, Priya Rasalam, Roy Diabetes Ther Review Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits, combined with low rates of hypoglycaemia across a wide range of patient characteristics. The safety and adverse event rate for tirzepatide appears comparable to that of GLP-1 receptor agonists. Although results from dedicated cardiovascular (CV) and kidney trials are currently not available, information to date suggests that tirzepatide may have CV and kidney benefits in people with T2D. Tirzepatide has been approved for the treatment of T2D in the USA, United Arab Emirates, European Union, Japan and Australia. Here, we review how tirzepatide will fit into the T2D treatment continuum. We also consider future directions with tirzepatide in T2D, including its potential for targeting cardio-renal-metabolic disease in T2D, and discuss how tirzepatide—and other co-agonists in development—may challenge current approaches for management of T2D. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01475-5. Springer Healthcare 2023-10-12 2023-12 /pmc/articles/PMC10597955/ /pubmed/37824027 http://dx.doi.org/10.1007/s13300-023-01475-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
MacIsaac, Richard J.
Deed, Gary
D’Emden, Michael
Ekinci, Elif I.
Hocking, Samantha
Sumithran, Priya
Rasalam, Roy
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title_full Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title_fullStr Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title_full_unstemmed Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title_short Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
title_sort challenging clinical perspectives in type 2 diabetes with tirzepatide, a first-in-class twincretin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597955/
https://www.ncbi.nlm.nih.gov/pubmed/37824027
http://dx.doi.org/10.1007/s13300-023-01475-5
work_keys_str_mv AT macisaacrichardj challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT deedgary challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT demdenmichael challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT ekincielifi challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT hockingsamantha challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT sumithranpriya challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin
AT rasalamroy challengingclinicalperspectivesintype2diabeteswithtirzepatideafirstinclasstwincretin